Table 2. The characteristics of the procedures.
| Overall (n = 44) | Cilostazol (+) (n = 22) | Cilostazol (−) (n = 22) | P value | |
|---|---|---|---|---|
| Number of treated lesions, n (%) | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) | 0.87 |
| Target Vessel, n (%) | ||||
| LMT | 2 (4.6%) | 1 (4.6%) | 1 (4.6%) | 1.00 |
| RCA | 18 (40.9%) | 10 (45.5%) | 8 (36.4%) | 0.54 |
| LAD | 32 (72.7%) | 16 (72.7%) | 16 (72.7%) | 1.00 |
| LCX | 14 (31.8%) | 6 (27.3%) | 8 (36.4%) | 0.52 |
| De novo, n (%) | 41 (93.2%) | 22 (100.0%) | 19 (86.4%) | 0.07 |
| ISR, n (%) | 8 (18.2%) | 4 (18.2%) | 4 (18.2%) | 1.00 |
| Type B2 or C, n (%) | 12 (27.3%) | 6 (27.3%) | 6 (27.3%) | 1.00 |
| Previous PCI, n (%) | 11 (25%) | 7 (31.8%) | 4 (18.2%) | 0.30 |
| Previous CABG, n (%) | 1 (2.3%) | 1 (4.6%) | 0 (0%) | 0.31 |
| DES usage, n (%) | 35 (79.6%) | 19 (86.4%) | 16 (72.8%) | 0.26 |
| Stent diameter, mm | 3.0 (3.0–3.5) | 3.0 (2.75–3.5) | 3.5 (3–3.5) | 0.48 |
| Stent length, mm | 18 (15–23) | 18.0 (15.0–23.0) | 18.0 (14.0–23.0) | 0.78 |
| Stent number, n | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) | 1.5 (1.0–2.3) | 0.66 |
| Stent number per vessel, n | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) | 0.62 |
| TVR (6–9 months), n (%) | 9 (20.5%) | 5 (22.7%) | 4 (18.2%) | 0.71 |
| TLR (6–9 months), n (%) | 7 (15.9%) | 4 (18.2%) | 3 (13.6%) | 0.68 |
Data are n (%) or median and (interquartile range). LMT, left main trunk; RCA, right coronary artery; LAD, left anterior descending; LCX, left circumflex; ISR, in-stent restenosis; Previous PCI, previous percutaneous coronary intervention; Previous CABG, previous coronary artery bypass graft; DES, drug-eluting stent; TLR, target lesion revascularization; TVR target vessel revascularization.